Published in Neurosignals on December 05, 2007
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol (2010) 2.12
Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS One (2011) 1.66
Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging (2010) 1.30
Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology (2013) 1.16
Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol Aging (2010) 1.09
Lifestyle and genetic contributions to cognitive decline and hippocampal structure and function in healthy aging. Curr Alzheimer Res (2012) 1.09
Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol Dis (2008) 1.01
Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease. J Alzheimers Dis (2012) 1.01
Quantitative plasma proteomic profiling identifies the vitamin E binding protein afamin as a potential pathogenic factor in SIV induced CNS disease. J Proteome Res (2010) 0.94
CSF Biomarkers for Alzheimer's Disease Diagnosis. Int J Alzheimers Dis (2010) 0.94
Physical activity and brain function in older adults at increased risk for Alzheimer's disease. Brain Sci (2013) 0.88
Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Toxicol Lett (2008) 0.87
Relationship between changes in brain MRI and (1)H-MRS, severity of chronic liver damage, and recovery after liver transplantation. Exp Biol Med (Maywood) (2009) 0.84
Olfactory functions scale with circuit restoration in a rapidly reversible Alzheimer's disease model. J Neurosci (2013) 0.83
CSF biomarkers in different phenotypes of Parkinson disease. J Neural Transm (Vienna) (2011) 0.83
Functional magnetic resonance imaging of semantic memory as a presymptomatic biomarker of Alzheimer's disease risk. Biochim Biophys Acta (2011) 0.82
Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J Alzheimers Dis (2014) 0.82
Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. EPMA J (2010) 0.81
Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases. Neurotherapeutics (2009) 0.80
The prognostic value of amyloid imaging. Eur J Nucl Med Mol Imaging (2012) 0.80
Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics. Int J Mol Sci (2014) 0.80
Neuroplastic effects of combined computerized physical and cognitive training in elderly individuals at risk for dementia: an eLORETA controlled study on resting states. Neural Plast (2015) 0.79
Cortical signatures of cognition and their relationship to Alzheimer's disease. Brain Imaging Behav (2012) 0.79
Biomarkers for cognitive impairment in Parkinson disease. Brain Pathol (2010) 0.78
Interactive effects of physical activity and APOE-ε4 on white matter tract diffusivity in healthy elders. Neuroimage (2015) 0.78
Relative contributions of biomarkers in Alzheimer's disease. Ann Epidemiol (2012) 0.76
Beta-Band Functional Connectivity is Reorganized in Mild Cognitive Impairment after Combined Computerized Physical and Cognitive Training. Front Neurosci (2016) 0.76
An image processing technique for diagnosis of Alzheimer's disease. J Res Med Sci (2009) 0.76
Biomarkers for the identification and treatment of dementia. Psychiatry (Edgmont) (2008) 0.75
Global prevalence of dementia: a Delphi consensus study. Lancet (2005) 23.30
Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol (2003) 14.87
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain (2006) 5.42
One-year age changes in MRI brain volumes in older adults. Cereb Cortex (2000) 5.16
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA (2001) 5.13
MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging (2001) 4.54
Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology (2006) 4.06
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov (2007) 4.03
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol (2003) 3.75
Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage (2003) 2.52
MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology (2005) 2.48
Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type. Neurology (2000) 2.31
Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx (2004) 2.02
Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology (2006) 1.85
Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol (2006) 1.81
Deformable registration of cortical structures via hybrid volumetric and surface warping. Neuroimage (2004) 1.74
Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci U S A (1999) 1.73
Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med (2003) 1.68
F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol (2005) 1.64
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 1.58
CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol (2002) 1.51
In vivo measurement of T1rho dispersion in the human brain at 1.5 tesla. J Magn Reson Imaging (2004) 1.38
Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal aging. Eur Neurol (1997) 1.36
Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia. Alzheimers Dement (2006) 1.34
SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology (2001) 1.27
Differential rates of regional brain change in callosal and ventricular size: a 4-year longitudinal MRI study of elderly men. Cereb Cortex (2002) 1.23
Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res (2004) 1.18
Differential associations between entorhinal and hippocampal volumes and memory performance in older adults. Behav Neurosci (2003) 1.17
In vivo measurement of plaque burden in a mouse model of Alzheimer's disease. J Magn Reson Imaging (2006) 1.13
Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl (2003) 1.12
CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol (2000) 1.06
Biological markers and the treatment of Alzheimer's disease. J Mol Neurosci (2001) 0.89
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol (1997) 6.12
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (2000) 5.62
A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science (1991) 5.60
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
One-year age changes in MRI brain volumes in older adults. Cereb Cortex (2000) 5.16
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1998) 4.07
A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem (2000) 3.97
Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci (2000) 3.90
Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron (1997) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron (1999) 3.49
An image-processing system for qualitative and quantitative volumetric analysis of brain images. J Comput Assist Tomogr (1998) 3.49
Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron (1993) 3.45
Epitopes that span the tau molecule are shared with paired helical filaments. Neuron (1988) 3.28
Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci (2001) 2.89
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology (2009) 2.84
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab (1992) 2.70
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Proteoglycan-induced changes in T1rho-relaxation of articular cartilage at 4T. Magn Reson Med (2001) 2.65
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology (2006) 2.65
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Past adult lead exposure is linked to neurodegeneration measured by brain MRI. Neurology (2006) 2.52
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol (1998) 2.47
Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology (2009) 2.45
CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology (2008) 2.43
Synucleinopathies: clinical and pathological implications. Arch Neurol (2001) 2.36
Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest (1992) 2.30
Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A (1999) 2.30
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology (2000) 2.27
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology (2004) 2.23
Finding parametric representations of the cortical sulci using an active contour model. Med Image Anal (1997) 2.22
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci (2001) 2.16
Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med (1997) 2.15
Two-stage expression of neurofilament polypeptides during rat neurogenesis with early establishment of adult phosphorylation patterns. J Neurosci (1987) 2.15
Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem (1999) 2.13
Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron (1994) 2.13
Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A (1998) 2.13
Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology (2005) 2.10
Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology (2007) 2.09
Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci U S A (1996) 2.08
Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen (2008) 2.00
Differences in cell-to-cell spread of pathogenic and apathogenic rabies virus in vivo and in vitro. J Virol (1985) 2.00
The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci U S A (1993) 1.99
Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol (1997) 1.98
A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res (2000) 1.97
Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J Cell Biol (1997) 1.95
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (2000) 1.92
Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci U S A (1999) 1.91
Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats. Exp Neurol (1998) 1.89
Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology (2010) 1.89
Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J (1998) 1.89
Age-dependent synuclein pathology following traumatic brain injury in mice. Exp Neurol (2003) 1.89
Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol (1991) 1.86
Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. Arch Neurol (2001) 1.84
Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology (2004) 1.82
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol (2000) 1.80
Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol (2000) 1.79
Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann Neurol (2001) 1.75
Phosphate dependent and independent neurofilament epitopes in the axonal swellings of patients with motor neuron disease and controls. Lab Invest (1987) 1.73
Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J Biol Chem (1995) 1.70
Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology (2003) 1.66
Progressive atrophy and neuron death for one year following brain trauma in the rat. J Neurotrauma (1997) 1.64
Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol (2000) 1.63
Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology (2010) 1.63
Experimental brain injury induces regionally distinct apoptosis during the acute and delayed post-traumatic period. J Neurosci (1998) 1.62
Evidence of apoptotic cell death after experimental traumatic brain injury in the rat. Am J Pathol (1995) 1.62
Enduring cognitive, neurobehavioral and histopathological changes persist for up to one year following severe experimental brain injury in rats. Neuroscience (1998) 1.60
Spine radiographs in patients with low-back pain. An epidemiological study in men. J Bone Joint Surg Am (1984) 1.60
Mild head injury increasing the brain's vulnerability to a second concussive impact. J Neurosurg (2001) 1.59
An adaptive-focus statistical shape model for segmentation and shape modeling of 3-D brain structures. IEEE Trans Med Imaging (2001) 1.59